Clinical Trials Logo

Dystrophic Epidermolysis Bullosa clinical trials

View clinical trials related to Dystrophic Epidermolysis Bullosa.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05157958 Recruiting - Clinical trials for Dystrophic Epidermolysis Bullosa

Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa

Start date: May 1, 2023
Phase: Phase 2
Study type: Interventional

After confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the time of enrollment using pre-designed block randomization scheme.

NCT ID: NCT04917887 Recruiting - Clinical trials for Recessive Dystrophic Epidermolysis Bullosa

Long-Term Follow-up Protocol

Start date: May 25, 2021
Phase:
Study type: Observational

The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).

NCT ID: NCT04757727 Recruiting - Clinical trials for Dystrophic Epidermolysis Bullosa

Gynecological Follow-up of Patients With Dystrophic Epidermolysis Bullosa (EBD)

Start date: January 1, 2021
Phase:
Study type: Observational

Dystrophic epidermolysis bullosa is a rare genetic pathology resulting in fragility of the skin and mucous membranes, causing bubbles and wounds following trauma. Scarring is pathological with a tendency to retraction. The gynecological and in particular the vulvovaginal mucous membranes can be affected but no description of any series is available in the literature. Likewise, some of these patients have a sexual and obstetrical life, despite sometimes-severe damage, but again no specific data is available. The investitigator thus wish to carry out a non-interventional multicenter prospective descriptive study. Better knowledge of gynecological semiology in patients with EBD will allow better adaptation of gynecological follow-up, screening for STDs and gynecological cancers, as well as possible specific complications. This study would eventually allow the draw up of recommendations for our gynecologist / obstetrician colleagues.